Servier is paying $1.8 billion upfront for the oncology assets, with the total value of the deal potentially rising to $2 billion if Agios’ key pipeline candidate vorasidenib – a dual ...

Introduction: A study was undertaken in patients with essential hypertension to compare, by ambulatory blood pressure monitoring, the response to a fixed low dose of ...